Longeveron LGVN Investor Presentation April 2024

Longeveron is a mid-clinical stage regenerative medicine company developing Lomecel-B™, an allogeneic medicinal signaling cell therapy derived from bone marrow. The company is advancing programs in Alzheimer's Disease and Aging-related Frailty through Phase 2 trials, with recent positive CLEARMIND Phase 2a results in mild-AD and five-year survival data from Phase 1 in Hypoplastic Left Heart Syndrome.